Caricamento quotazioni...
Previsioni
Non sono disponibili dati degli analisti per questa azienda.
Discussioni nella community
- EuropÀische Aktien
Ich suche derzeit nach guten Investitionsmöglichkeiten in Europa, um meine US Gewichtung etwas nach unten zu bringen. Ich schaue mir gerade die London Stock Exchange und Kongsberg Gruppen an. BereitsâŠ
u user_ce10af IV in Schnack
0 13 - TR - Probleme beim login in die Web App
Hallo, Ich habe heute den gesamten Tag ĂŒber versucht mich in die Web App von Trade Republic einzuloggen. (Ich wollte mir meine Transaktionen und andere Dokumente sichern) Nach Eingabe der PIN erhalteâŠ
Jens V in Schnack 0 21
Notizie Vai al feed delle notizie
Coloplast A-S announces quarterly results for 03.11.2026
Coloplast A-S will release results on 03.11.2026 for the quarter ended 30.09.2026. Eleven analysts on average estimate EPS for the quarter at 5.91 DKK versus 3.88 DKK a year earlier, and 15 analysts forecast revenue of 7.40 bn DKK versus 6.96 bn DKK in the year-ago quarter. For the most recently completed fiscal year, 22 analysts predict EPS of 25.45 DKK (prev. year 16.13 DKK) and 23 analysts expect annual revenue of 28.88 bn DKK (prev. year 27.87 bn DKK). » Altro su finanzen.net
Coloplast A-S expects slight revenue growth and higher EPS for Q3, results on Nov. 3
Coloplast A-S will release results for the quarter ended Sept. 30 on Nov. 3. Ten analysts see an average EPS of USD 0.090 versus USD 0.060 a year earlier. Quarterly revenues are forecast on average at USD 1.12 billion (+2.6% year-on-year). For the past fiscal year analysts on average expect EPS of USD 0.385 and revenue of USD 4.38 billion. » Altro su finanzen.net
Coloplast share falls after downgrade by JPMorgan
Coloplastâs share dropped 3.3% and fell intraday to as low as 427.8 DKK after JPMorgan cut its rating from "Neutral" to "Underweight" and lowered the December 2027 price target from 484 DKK to 377 DKK (about â22%). The bank cited a high P/E ratio of 35.35 and a valuation premium of roughly 20% versus the medtech sector, while earnings growth lags the industry. JPMorgan also noted governance uncertainty and expects the new CEO is likely to revise midâterm financial targets down when results are presented on 3 November; weak Q3 margins and increased short interest add further pressure. » Altro su de.investing.com
Coloplast A-S (B) announces quarterly results for period to 30 June 2026
Coloplast A-S (B) will present the numbers for the quarter to 30 June 2026 on 18 August 2026. Ten analysts expect on average an EPS of 6.08 DKK versus 3.57 DKK in the prior year. Fourteen analysts forecast revenue of on average 7.26 billion DKK, an increase of 4.34% versus the year-earlier quarter. For the current fiscal year, consensus estimates are 24.88 DKK earnings per share and 28.79 billion DKK revenue. » Altro su finanzen.net
Coloplast A-S (spons ADRs) announces quarterly results for June 30, 2026
Coloplast A-S (spons ADRs) will present results for the quarter ended June 30, 2026 on August 18, 2026. Nine analysts expect EPS of on average $0.093 (prior year $0.050); 13 analysts forecast revenue of about $1.11 billion (up 5.4% from $1.06 billion). For the current fiscal year, consensus estimates are $0.382 EPS and $4.43 billion in revenue (prior year: $0.240 / $4.12 billion). » Altro su finanzen.net
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 997,78Â Mln | 7,01% |
| Utile lordo | 653,6Â Mln | 23,42% |
| Utile netto | 158,65Â Mln | 35,34% |
| EBITDA | 243,33Â Mln | 13,96% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 15,38 Mld ⏠|
Numero di azioni | 225,37Â Mln |
Massimo/minimo a 52 settimane | 79,14 ⏠- 49,46 ⏠|
Rendimento da dividendo | 4,57% |
Dividendi TTM | 3,08 ⏠|
Beta | 0,57 |
Rapporto P/E | 37,40 |
Rapporto PEG | -2,42 |
Rapporto P/B | 8,05 |
Rapporto P/S | 3,97 |
Profilo aziendale
Coloplast A/S sviluppa, produce e commercializza prodotti medicali. L'azienda Ăš impegnata nello sviluppo, nel marketing e nella vendita di prodotti e servizi per la salute intima, rivolti a persone affette da patologie di natura privata e personale. Le sue attivitĂ sono strutturate in quattro aree di business: Ostomy Care, che offre prodotti per persone il cui tratto intestinale Ăš stato deviato attraverso la parete addominale; Continence Care, con prodotti per persone affette da patologie e danni al sistema urinario; Urology Care, con prodotti per persone affette da patologie e danni a reni, sistema urinario o apparato riproduttivo maschile; e Wound & Skin Care, per il trattamento delle ferite croniche e prodotti per la cura della pelle per la prevenzione e il trattamento. L'azienda fornisce prodotti a ospedali, istituzioni, grossisti e farmacie.
| Nome | COLOPLAST |
| CEO | Gavin Wood |
| Sede centrale | HumlebĂŠk,
ze Danimarca |
| Sito web | |
| Settore | SanitĂ |
| Industria | Attrezzature e forniture sanitarie |
| Quotazione in borsa | 24/01/2007 |
| Dipendenti | 17.270 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
XETRA | CBHD.DE |
Pnk | CLPBF |
Nasdaq Copenhagen | COLO-B.CO |
Copenhagen | COLO B.CO |
Frankfurt | CBHD.F |
DĂŒsseldorf | CBHD.DU |
London | 0QBO.L |
SIX | COLOB.SW |
MĂŒnchen | CBHD.MU |
Wien | COLO.VI |